ArticleJournal of gastroenterology2019

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.

Masahiro Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.